vs

Side-by-side financial comparison of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

Riley Exploration Permian, Inc. is the larger business by last-quarter revenue ($97.3M vs $49.9M, roughly 2.0× MARAVAI LIFESCIENCES HOLDINGS, INC.). On growth, Riley Exploration Permian, Inc. posted the faster year-over-year revenue change (-5.3% vs -11.8%). Over the past eight quarters, Riley Exploration Permian, Inc.'s revenue compounded faster (-1.2% CAGR vs -11.9%).

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

MRVI vs REPX — Head-to-Head

Bigger by revenue
REPX
REPX
2.0× larger
REPX
$97.3M
$49.9M
MRVI
Growing faster (revenue YoY)
REPX
REPX
+6.6% gap
REPX
-5.3%
-11.8%
MRVI
Faster 2-yr revenue CAGR
REPX
REPX
Annualised
REPX
-1.2%
-11.9%
MRVI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MRVI
MRVI
REPX
REPX
Revenue
$49.9M
$97.3M
Net Profit
$-35.7M
Gross Margin
25.8%
Operating Margin
-117.9%
26.9%
Net Margin
-71.6%
Revenue YoY
-11.8%
-5.3%
Net Profit YoY
-37.7%
EPS (diluted)
$-0.24
$4.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVI
MRVI
REPX
REPX
Q4 25
$49.9M
$97.3M
Q3 25
$41.6M
$106.9M
Q2 25
$47.4M
$85.4M
Q1 25
$46.9M
$102.5M
Q4 24
$56.6M
$102.7M
Q3 24
$69.0M
$102.3M
Q2 24
$69.4M
$105.4M
Q1 24
$64.2M
$99.7M
Net Profit
MRVI
MRVI
REPX
REPX
Q4 25
$-35.7M
Q3 25
$-25.6M
$16.3M
Q2 25
$-39.6M
$30.5M
Q1 25
$-29.9M
$28.6M
Q4 24
$-25.9M
Q3 24
$-97.1M
$25.7M
Q2 24
$-9.8M
$33.5M
Q1 24
$-12.1M
$18.8M
Gross Margin
MRVI
MRVI
REPX
REPX
Q4 25
25.8%
Q3 25
13.6%
Q2 25
16.4%
Q1 25
16.5%
Q4 24
34.3%
Q3 24
46.7%
Q2 24
44.4%
Q1 24
40.3%
Operating Margin
MRVI
MRVI
REPX
REPX
Q4 25
-117.9%
26.9%
Q3 25
-98.6%
27.0%
Q2 25
-139.8%
33.7%
Q1 25
-104.9%
48.3%
Q4 24
-66.7%
31.2%
Q3 24
-239.9%
17.1%
Q2 24
-19.4%
50.9%
Q1 24
-29.4%
50.7%
Net Margin
MRVI
MRVI
REPX
REPX
Q4 25
-71.6%
Q3 25
-61.4%
15.3%
Q2 25
-83.5%
35.7%
Q1 25
-63.9%
27.9%
Q4 24
-45.8%
Q3 24
-140.6%
25.1%
Q2 24
-14.1%
31.8%
Q1 24
-18.8%
18.8%
EPS (diluted)
MRVI
MRVI
REPX
REPX
Q4 25
$-0.24
$4.02
Q3 25
$-0.18
$0.77
Q2 25
$-0.27
$1.44
Q1 25
$-0.21
$1.36
Q4 24
$-0.21
$0.52
Q3 24
$-0.68
$1.21
Q2 24
$-0.07
$1.59
Q1 24
$-0.09
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVI
MRVI
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$216.9M
Total DebtLower is stronger
$291.8M
$247.9M
Stockholders' EquityBook value
$212.4M
$634.2M
Total Assets
$770.6M
$1.2B
Debt / EquityLower = less leverage
1.37×
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVI
MRVI
REPX
REPX
Q4 25
$216.9M
Q3 25
$243.6M
Q2 25
$269.9M
Q1 25
$285.1M
Q4 24
$322.4M
Q3 24
$578.2M
Q2 24
$573.2M
Q1 24
$561.7M
Total Debt
MRVI
MRVI
REPX
REPX
Q4 25
$291.8M
$247.9M
Q3 25
$292.8M
$367.0M
Q2 25
$293.9M
$275.2M
Q1 25
$294.9M
$249.3M
Q4 24
$295.9M
$269.5M
Q3 24
$521.7M
$288.6M
Q2 24
$522.5M
$322.7M
Q1 24
$523.3M
$341.8M
Stockholders' Equity
MRVI
MRVI
REPX
REPX
Q4 25
$212.4M
$634.2M
Q3 25
$245.4M
$566.5M
Q2 25
$265.9M
$556.9M
Q1 25
$300.6M
$532.4M
Q4 24
$325.3M
$510.6M
Q3 24
$344.9M
$507.4M
Q2 24
$434.7M
$489.0M
Q1 24
$410.7M
$434.6M
Total Assets
MRVI
MRVI
REPX
REPX
Q4 25
$770.6M
$1.2B
Q3 25
$849.2M
$1.2B
Q2 25
$897.0M
$1.0B
Q1 25
$959.8M
$994.9M
Q4 24
$1.0B
$993.5M
Q3 24
$1.3B
$997.9M
Q2 24
$1.4B
$1.0B
Q1 24
$1.4B
$956.4M
Debt / Equity
MRVI
MRVI
REPX
REPX
Q4 25
1.37×
0.39×
Q3 25
1.19×
0.65×
Q2 25
1.11×
0.49×
Q1 25
0.98×
0.47×
Q4 24
0.91×
0.53×
Q3 24
1.51×
0.57×
Q2 24
1.20×
0.66×
Q1 24
1.27×
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVI
MRVI
REPX
REPX
Operating Cash FlowLast quarter
$-22.8M
$64.9M
Free Cash FlowOCF − Capex
$-24.9M
FCF MarginFCF / Revenue
-49.9%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVI
MRVI
REPX
REPX
Q4 25
$-22.8M
$64.9M
Q3 25
$-15.2M
$63.6M
Q2 25
$-10.3M
$33.6M
Q1 25
$-9.4M
$50.4M
Q4 24
$-14.6M
$66.4M
Q3 24
$13.1M
$72.1M
Q2 24
$17.4M
$51.6M
Q1 24
$-8.5M
$56.1M
Free Cash Flow
MRVI
MRVI
REPX
REPX
Q4 25
$-24.9M
Q3 25
$-18.1M
Q2 25
$-13.1M
Q1 25
$-14.6M
Q4 24
$-20.5M
Q3 24
$4.5M
Q2 24
$7.9M
Q1 24
$-14.1M
FCF Margin
MRVI
MRVI
REPX
REPX
Q4 25
-49.9%
Q3 25
-43.4%
Q2 25
-27.7%
Q1 25
-31.2%
Q4 24
-36.2%
Q3 24
6.6%
Q2 24
11.4%
Q1 24
-22.0%
Capex Intensity
MRVI
MRVI
REPX
REPX
Q4 25
4.2%
Q3 25
7.0%
Q2 25
6.1%
Q1 25
11.2%
Q4 24
10.3%
Q3 24
12.4%
Q2 24
13.8%
Q1 24
8.8%
Cash Conversion
MRVI
MRVI
REPX
REPX
Q4 25
Q3 25
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

REPX
REPX

Segment breakdown not available.

Related Comparisons